Previous 10 | Next 10 |
2023-08-11 09:56:34 ET Major earnings expected before the bell on Monday include: Atossa Therapeutics ( ATOS ) JinkoSolar Holding ( JKS ) Niu Technologies ( NIU ) Sundial Growers ( SNDL ) 22nd Century Group ( XXII ) For further details see: ...
SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in cancer, today announced that it will provide a business update and report financial results for the...
2023-07-20 15:25:20 ET Shares of Atossa Therapeutics ( NASDAQ: ATOS ) traded higher Thursday after the oncology-focused biotech said that Canadian health regulators issued a "No Objection Letter" regarding its request to conduct a Phase 2 trial for a breast cancer therapy. The d...
SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Health Canada has issued a ...
2023-07-13 16:28:19 ET Biopharmaceutical company Atossa Therapeutics ( NASDAQ: ATOS ) said on Thursday that it has regained compliance with Nasdaq's minimum closing bid price requirement. The company was notified of the non-compliance on Oct. 5. The requirement for continu...
SEATTLE, July 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that on July 13, 2023 it received w...
SEATTLE, WA / ACCESSWIRE / July 12, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual physiology plays a huge factor. Women with dense breast tissue face a higher risk of deve...
SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that 170 patients have been enrolle...
SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces a strategic, sponsored research...
--News Direct-- Atossa Therapeutics CEO Steven Quay joined Proactive's Natalie Stoberman to discuss the latest progress in its Phase 2 I-SPY 2 clinical trial where six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, ac...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa’s ...